B Adjusted mean c P< 0.05 for treatment difference.
B Gecorrigeerd gemiddelde c P< 0, 05 voor een verschil in behandeling.
Treatment difference.
Verschil in behandlingen.
with a statistically significant estimated treatment difference of -3.57 mmHg p< 0.001.
met een statistisch significant geschat behandelingsverschil van-3, 57 mmHg p< 0, 001.
Treatment difference.
Verschil door behandeling.
With ABC/3TC vs 89.2% with TDF/FTC, when taken with efavirenz as third drug, treatment difference -1.8% 95% CI -7.5%, 3.9.
Met ABC/3TC versus 89,2% met TDF/FTC in combinatie met efavirenz als derde geneesmiddel, behandelingsverschil-1,8% 95% BI-7,5%, 3, 9.
Treatment difference.
Verschil in behandelingen.
A similar virologic response was observed for both regimens point estimate for treatment difference at week 48:
Een vergelijkbare virologische respons werd bij beide regimes waargenomen puntschatting voor het verschil in behandeling na 48 weken: 0,39%,
Treatment difference.
Verschil tussen behandelingen.
During the 12-week treatment period, patients treated with Fexeric had a significant decrease in serum phosphorus, compared to the placebo group(p< 0.001 for treatment difference) Table 3.
Tijdens de 12 weken durende behandelingsperiode trad bij patiënten die met Fexeric behandeld werden ten opzichte van de placebogroep een significante daling van het serumfosforgehalte op(p< 0, 001 voor het verschil in behandeling) tabel 3.
Treatment difference 95% CI.
Behandelingsverschil 95% BI.
HbA1c of 0.10% for patients taking metformin added to sulphonylurea, p=0.0083 for treatment difference.
versus een afname in HbA1c van 0,10% bij patiënten die metformine toegevoegd kregen aan sulfonylureumderivaten p=0, 0083 voor het behandelverschil.
Treatment difference 95%CI.
Verschil in behandeling 95% BI.
Observed treatment difference vs placebo.
Waargenomen behandelingsverschil versus placebo.
Treatment difference 95% CI.
Verschil tussen behandelingen 95% BI.
Two-sided CI on the treatment difference(Eurartesim- Comparator); p-value.
Tweezijdig BI over het behandelingsverschil(Eurartesim- comparator); p-waarde.
Treatment difference P value 95% CI.
Behandelverschil P-waarde 95% BI.
Adjusted treatment difference p-value versus placebo.
Mean Treatment Difference Compared with Placebo SE.
Gemiddeld behandelverschil in vergelijking met placebo SE.
Treatment Difference at Day 28[95% CI] b.
Behandelingsverschil op dag 28(95% BI) b.
Observed treatment difference vs placebo mean difference..
Waargenomen behandelingsverschil versus placebo gemiddeld verschil.
Treatment difference 95% CI of difference..
Verschil tussen behandelingen 95% BI van verschil..
P-Value for treatment difference in change from baseline ANOVA.
P-waarde voor behandelingverschil in verandering ten opzichte van baseline ANOVA.
Treatment difference for all ACR scores was significant p≤ 0.0001.
Het verschil van behandeling was voor alle ACR-scores significant p ≤ 0, 0001.
In the second study, the treatment difference in EET between ANORO 55/22 micrograms and placebo was 21.9 seconds(p=0.234)
In het tweede onderzoek bedroeg in week 12 het behandelverschil in EET tussen ANORO 55/22 microgram en placebo 21,
Uitslagen: 75,
Tijd: 0.0501
Hoe "treatment difference" te gebruiken in een Engels zin
We often don’t see an equal treatment difference happening at all three study weeks.
The period effect, second period minus first period, is estimated by the treatment difference for period 2 minus the treatment difference for period 1.
Treatment difference 0.11% with 95% CI (0.04%, 0.27%) indicates non-inferiority of albiglutide versus insulin glargine.
The conclusion of no treatment difference cannot be automatically translated into either equivalence or non-inferiority.
An analysis of covariance model was used to compare treatment difference in change from baseline.
Treatment difference was assumed to be statistically significant when p ≤ 0.05 unless otherwise stated.
The primary outcome was the treatment difference at week 12 in mean 24-hour systolic BP.
The orthodontic treatment in adults, children, the treatment difference appears as longer duration of treatment.
This treatment difference was more apparent in the subgroup of patients with PPS at baseline.
No significant treatment difference was noted among NM, LM, and AL between Caucasians and AAs.
English
Deutsch
Español
Français
عربى
Български
বাংলা
Český
Dansk
Ελληνικά
Suomi
עִברִית
हिंदी
Hrvatski
Magyar
Bahasa indonesia
Italiano
日本語
Қазақ
한국어
മലയാളം
मराठी
Bahasa malay
Norsk
Polski
Português
Română
Русский
Slovenský
Slovenski
Српски
Svenska
தமிழ்
తెలుగు
ไทย
Tagalog
Turkce
Українська
اردو
Tiếng việt
中文